Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H40FN5O2 |
Molecular Weight | 509.6586 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=O)N1CCC2=C(C1)N=C(C)N2[C@@H]3C[C@@H]4CC[C@H](C3)N4CC[C@H](NC(C)=O)C5=CC=CC(F)=C5
InChI
InChIKey=QETUKYDWZIRTEI-QUMGSSFMSA-N
InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25+,26-/m0/s1
Molecular Formula | C29H40FN5O2 |
Molecular Weight | 509.6586 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
PF-232798 is a potent oral CCR5 antagonist with a primary and selectivity/safety pharmacology profile similar to maraviroc (MVC). PF-232798 shows increased binding affinity and improved oral absorption compared to maraviroc. In addition, it retains activity against a laboratory generated maraviroc-resistant HIV-1 strain, indicating an alternative drug resistance profile. PF-232798 binds to the same pocket as MVC within the transmembrane region of CCR5, but shows additional interactions at the ECL2 hinge region. PF-232798 is well tolerated in normal volunteers. PF-232798 had been in a phase-II clinical trial for the treatment of HIV infections. However, this development was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). | 2011 Jan 13 |
|
Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5. | 2019 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.natap.org/2008/CROI/croi_112.htm
250mg QD, 7 days dosing
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:32:09 GMT 2023
by
admin
on
Sat Dec 16 05:32:09 GMT 2023
|
Record UNII |
63P7W7886U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
849753-15-7
Created by
admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
|
PRIMARY | |||
|
DTXSID40234029
Created by
admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
|
PRIMARY | |||
|
53316710
Created by
admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
|
PRIMARY | |||
|
63P7W7886U
Created by
admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
|
PRIMARY | |||
|
DB14813
Created by
admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |